Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price & Analysis
Ginkgo Bioworks Holdings, Inc. (DNA) closed at USD 9.99 on Friday, October 23, 2026, up 2.88% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 9.71; the Oct 23, 2026 session ranged USD 9.43–9.99 on volume of 1,149,795 shares. Market capitalization is $672.73M, with a 52-week range of USD 5.37–18.22 (NYQ). Source: Nexqual, retrieved October 24, 2026 at 01:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DNA.md
Key facts (DNA)
- Last four reported quarters (through Jun 30, 2026): revenue $112M, net income -$291M (-260.0% margin), free cash flow -$175M (SEC filings).
- 1 of 80 tracked superinvestors hold DNA (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 16 Form 4 filings, $4.9M; 15 not under a Rule 10b5-1 plan ($4.9M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Sell (mean 4.00 on a 1–5 scale) (3 analysts), mean target USD 8 (range 5–11).
- Total return with dividends: 1Y -26.4% vs S&P 500 +13.4%; 5Y -98.2% vs S&P 500 +76.9%.
- Next earnings: 2026-11-05, EPS estimate USD -0.54, revenue estimate $21.5M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DNA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $314M | $478M | $251M | $227M | $170M | $112M |
| Operating income | -$1.83B | -$2.21B | -$864M | -$560M | -$315M | -$291M |
| Net income | -$1.83B | -$2.10B | -$893M | -$547M | -$313M | -$291M |
| EPS (diluted) | -$55.60 | -$50.20 | -$18.37 | -$10.54 | -$5.64 | — |
| Free cash flow | -$310M | -$304M | -$336M | -$382M | -$179M | -$175M |
| Operating margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% | -259.9% |
| Net margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% | -260.0% |
| Revenue growth | +309.4% | +52.2% | -47.4% | -9.7% | -25.1% | — |
| Cash + short-term investments | $1.55B | $1.32B | $944M | $562M | $423M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DNA)
P/S 6.0x · P/B 1.6x · FCF yield -25.98% · Earnings yield -43.23%
Superinvestors (SEC 13F-HR, Q2 2026) (DNA)
1 of 80 tracked investors hold DNA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.10% | $35.4M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (DNA)
1 of 16 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Coen Steven P. | See remarks | 766 | $8K | 1.5% | No | Too little history (no open-market trades in 2023) |
| 2026-10-19 | Canton Barry | 41,172 | $418K | 4.8% | No | Too little history (no open-market trades in 2024 or 2025) | |
| 2026-10-19 | Shetty Reshma P. | See remarks | 41,172 | $418K | 4.8% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-10-19 | Kelly Jason R | See remarks | 45,682 | $463K | 26.1% | No | Too little history (no open-market trades in 2025) |
| 2026-10-05 | Coen Steven P. | See remarks | 2,403 | $36K | 4.6% | Yes | Too little history (no open-market trades in 2023) |
| 2026-09-15 | Henry Christian O | Director | 5,000 | $35K | 20.6% | No | Too little history (no open-market trades in 2024) |
| 2026-08-24 | Coen Steven P. | See remarks | 330 | $2K | 0.6% | No | Too little history (no open-market trades in 2023) |
| 2026-07-17 | Coen Steven P. | See remarks | 752 | $6K | 1.4% | No | Too little history (no open-market trades in 2023) |
| 2026-05-22 | Coen Steven P. | See remarks | 307 | $3K | 0.6% | No | Too little history (no open-market trades in 2023) |
| 2026-04-17 | Coen Steven P. | See remarks | 324 | $3K | 0.6% | No | Too little history (no open-market trades in 2023) |
| 2026-04-13 | Coen Steven P. | See remarks | 33,171 | $213K | 40% | No | Too little history (no open-market trades in 2023) |
| 2026-04-10 | Canton Barry | 124,727 | $802K | 22.2% | No | Too little history (no open-market trades in 2024 or 2025) | |
| 2026-04-10 | Shetty Reshma P. | See remarks | 124,727 | $802K | 22.2% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-04-08…2026-04-09 | Shetty Reshma P. | See remarks | 26,271 | $175K | 7.2% | No | Too little history (no open-market trades in 2024 or 2025) |
| 2026-04-08…2026-04-09 | Canton Barry | 26,271 | $175K | 7.2% | No | Too little history (no open-market trades in 2024 or 2025) | |
| 2026-04-08…2026-04-09 | Kelly Jason R | See remarks | 206,782 | $1.4M | 39.5% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DNA)
Consensus Sell (mean 4.00 on a 1–5 scale), 3 analysts; mean target USD 8 (low 5, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Hold | $9 → $11 |
| 2026-09-04 | BTIG | Reiterated | Sell | $5 |
| 2026-08-07 | TD Cowen | Downgrade | Buy → Hold | $12 → $9 |
Total return (dividends reinvested) (DNA)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -26.4% | -98.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -26.5% | -55.2% |
| Volatility (annualized) | 100.5% | 97.3% |
| Max drawdown | -59.6% (Oct 2025→Mar 2026) | -99.0% (Nov 2021→Mar 2025) |
DNA revenue by product line (quarter ended Sep 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Cell Engineering | $29.4M | 75.6% | -60.9% |
| Biosecurity | $9.5M | 24.4% | -32.2% |
| Total revenue | $38.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DNA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | THERMO FISHER SCIENTIFIC INC. (TMO) | “In particular, we rely on Twist for custom DNA synthesis and Thermo Fisher Scientific Inc. and others for certain instruments and consumables.” |
| Partner | Alphabet (Google) (GOOGL) | “Because of our access to large amounts of data, which is critical to efficiently leverage AI, Ginkgo is well-positioned to build superior foundational models and from there, build fine-tuned models designed to cater to our customer needs, all powered by our partnership with Google Cloud.” |
| Partner | SYNLOGIC, INC. (SYBX) | “The Company has also partnered with existing entities, including Genomatica, Inc. ("Genomatica") and Synlogic, Inc. ("Synlogic") (collectively, "Legacy Structured Partnerships") with complementary assets for synthetic biology applications.” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name DNA in their SEC reports
| Relationship to DNA | Company | Filing | Sentence |
|---|---|---|---|
| partner | XWELL, Inc. (XWEL) | 10-K Apr 1, 2026 | “As of December 31, 2023, the Company closed all XpresCheck locations and XpresTest no longer provides diagnostic testing services XpresTest began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks") in 2021.” |
| partner | AGENUS INC (AGEN) | 10-K Mar 16, 2026 | “In January 2019, we announced that the Bill & Melinda Gates Foundation awarded us a grant to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of QS-21 STIMULON adjuvant which our subsidiary, SaponiQx, is pursuing in partnership with Phyton Biotech and Ginkgo Bioworks.” |
| partner | SYNLOGIC, INC. (SYBX) | 10-K Mar 12, 2026 | “Other charges relating to the restructuring include a $5.2 million charge to impairment for prepaid research and development in relation to the Ginkgo collaboration (See Note 11, Collaboration Agreements, in the audited financial statements included in the 2024 Annual Report) for the year ended December 31, 2024.” |
DNA customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 15% of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name it.
DNA company outlook (results filed Aug 5, 2026)
- “Outlook • Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.”
- “The presentation will include an overview of the second quarter 2026, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.”
Quoted word-for-word from the SEC 8-K results press release.
DNA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.54 | $0.00 | — | $21.5M | 2 |
| Next quarter (ends Dec 2026) | $-0.82 | $0.00 | — | $23.8M | 1 |
| Current fiscal year (ends Dec 2026) | $-2.93 | $-3.42 | -14.3% | $85.1M | 2 |
| Next fiscal year (ends Dec 2027) | $-2.90 | $-3.21 | -9.7% | $96.2M | 1 |
DNA options: expected move
Options price a move of about ±28.0% (±$2.80) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±13.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 127.5% | ±28.0% |
| Dec 18, 2026 | 56 | 106.8% | ±33.0% |
| Jan 15, 2027 | 84 | 100.2% | ±37.8% |
| Mar 19, 2027 | 147 | 106.9% | ±52.6% |
| May 21, 2027 | 210 | 106.7% | ±61.8% |
| Jun 17, 2027 | 237 | 104.1% | ±63.8% |
| Aug 20, 2027 | 301 | 107.7% | ±73.6% |
| Nov 19, 2027 | 392 | 113.1% | ±86.1% |
30-day implied volatility 113% vs 140.6% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 01:36 UTC)
| Price | USD 9.99 |
|---|---|
| Change | ▲ 2.88% (up) |
| Previous Close | USD 9.71 |
| Open | USD 9.61 |
| Day Range | USD 9.43 – 9.99 |
| 52-Week Range | USD 5.37 – 18.22 |
| Volume | 1,149,795 shares |
| Market Cap | $672.73M |
| Exchange | NYQ |
Technical Analysis (DNA)
Nexqual's technical model rates DNA "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 24, 2026 at 01:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.86 (neutral) |
| vs SMA50 | Above (USD 9.07) |
| MACD | 0.16 (positive) |
Analyst Ratings (DNA)
Wall Street analysts rate DNA "Sell" based on 3 analysts, with a mean price target of USD 8 (range USD 5–11), per Nexqual as of October 24, 2026 at 01:36 UTC.
| Consensus Rating | Sell |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 8 |
| High Target | USD 11 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 0 / 1 / 2 |
Earnings (DNA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.54 |
| Revenue Estimate | $21.51M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.73 vs est -0.7 ▼ miss |
| 2026-03-31 | USD -1.39 vs est -1.34 ▼ miss |
| 2025-12-31 | USD -0.77 vs est -1.11 ▲ beat |
| 2025-09-30 | USD -1.45 vs est -1.24 ▼ miss |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Financials & Fundamentals (DNA)
| Total Revenue | $132.42M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -48.50% |
| Gross Margin | +68.04% |
| Operating Margin | -284.99% |
| Profit Margin | -219.61% |
| ROE | -59.94% |
| Debt / Equity | 0.96 |
| Current Ratio | 4.57 |
| Total Cash | $302.16M |
| Total Debt | $404.11M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$174.80M (-156.3% of revenue) |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Financial Health Score (DNA)
Nexqual rates Ginkgo Bioworks Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 01:36 UTC.
| Growth | Critical — Revenue -25% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $302M cash vs $404M debt |
| Cash Flow | Weak — FCF negative: -$175M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -60%, ROA -16.7% |
Ownership (DNA)
| Insider Ownership | +4.56% |
|---|---|
| Institutional Ownership | +73.65% |
| Shares Outstanding | 55.38M |
| Float | 49.88M |
| Short % of Float | +13.64% |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
Leadership (DNA)
Ginkgo Bioworks Holdings, Inc. is led by Jason Kelly, Co-Founder, Co-COO, CEO & Director, per Nexqual as of October 24, 2026 at 01:36 UTC.
| Co-Founder, Co-COO, CEO & Director | Jason Kelly |
|---|---|
| Co-Founder, President & Director | Reshma P. Shetty |
| Chief Financial Officer | Steven P. Coen |
| Co-Founder & CTO | Bartholomew Canton |
| Co-Chief Operating Officer | Jennifer Wipf |
Major Backers & Investors (DNA)
Notable institutional backers of Ginkgo Bioworks Holdings, Inc. include Viking Global, Erste Asset Management GmbH, Baillie Gifford, according to Nexqual as of October 24, 2026 at 01:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Viking Global | 6.46% |
| Erste Asset Management GmbH | 4.58% |
| Baillie Gifford | 4.32% |
| Anchorage Capital Group, LLC | 3.15% |
| Forbes, J.M. & Company | 1.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.73% |
| Vanguard Group | 3.77% |
| Legal & General Group PLC | 3.01% |
| State Street | 2.66% |
| Geode Capital | 2.21% |
Source: Nexqual, October 24, 2026 at 01:36 UTC.
From Ginkgo Bioworks Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our biologics services support the development and optimization of therapeutic proteins, peptides, enzymes, and other biological products using AI-driven protein engineering and our proprietary production platforms, including high-output methanol-free Pichia pastoris strains.
- Our capabilities include validated in vitro and in planta screening assays that enable confident selection of lead candidates, extensive expertise in scaling up active ingredients including both Cry proteins and novel bioactives, and access to our proprietary collection of over 315,000 strains isolated from agriculturally relevant environments.
- We provide comprehensive R&D services for discovering and optimizing plant traits, leveraging our proprietary metagenomic library of over 2.7 billion genes (with less than 5% overlap with public databases).
- We have released a selection of these models on our Model API.
Partnerships
- Because of our access to large amounts of data, which is critical to efficiently leverage AI, Ginkgo is well-positioned to build superior foundational models and from there, build fine-tuned models designed to cater to our customer needs, all powered by our partnership with Google Cloud.
- A flagship example of our capabilities is our partnership with Bayer Crop Sciences, where we are developing biological solutions for nitrogen fixation in non-legume crops to reduce reliance on industrial fertilizers.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to comply with federal, state, local and international laws and regulations could adversely affect our business and our financial condition.
- We may also become subject to increasing regulation in the future as we expand our business.
- We may incur significant costs complying with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.
- Our business activities may be subject to regulation and enforcement by the FDA, U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt